Tonix Pharmaceuticals develops and sells prescription medicines for fibromyalgia and acute migraine. It last closed at $2.94 on Nov 17, up 2.08% on the day.
Only 1 firm rated TNXP in the past 90 days, not enough for a consensus
Average 12-month target
$18.00
▲ 512.2% upside
Based on 1 analyst who set a price target on TNXP in the past 90 days. The average target is $18.00, with a high of $18.00 and a low of $18.00, compared with the last close of $2.94.
Low $18.00Avg $18.00High $18.00
Blue marker: last close $2.94
Highest target$18.00
Average target$18.00
Lowest target$18.00
Latest rating changes
Canaccord GenuityInitiated
Oct 26Buy$18
Raymond JamesInitiated
Jun 25Buy$26
TD CowenInitiated
May 4Buy$22
Date
Firm
Action
Rating
Price target
Oct 26
Canaccord Genuity
Initiated
Buy
$18
Jun 25
Raymond James
Initiated
Buy
$26
May 4
TD Cowen
Initiated
Buy
$22
Loading…
Technical Analysis
TNXP · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 56% below its 20 day and 149% below its 50 day average. It is 296% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 13), oversold. The nearest support is the Pivot at $2.92, and the nearest resistance the Pivot R1 at $3.01.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.7%/day
Key levels
$20.5652 week high+599.3%
$11.65200 day average+296.3%
$9.72100 day average+230.6%
$7.3150 day average+148.6%
$5.38Swing high (Nov 4)+83.0%
$4.5720 day average+55.4%
$3.01Pivot R1+2.4%
$2.94Last close
$2.92Pivot−0.7%
$2.86Pivot S1−2.7%
$2.8152 week low−4.4%
Indicators
RSI (14)
12.71
Oversold below 30
Oversold
MACD
-1.16
Below its signal line
Bearish
Stochastic
3.9
Near the bottom of its range
Oversold
ADX (14)
69.5
Strong downtrend
Williams %R
-95.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-155.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−43.4%
Change over 10 sessions
Bearish
ATR (14)
$0.43
Typical daily range, 14.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 57.7%/day
Key levels
$20.5652 week high+599.3%
$11.65200 day average+296.3%
$9.72100 day average+230.6%
$7.3150 day average+148.6%
$5.38Swing high (Nov 4)+83.0%
$4.5720 day average+55.4%
$3.01Pivot R1+2.4%
$2.94Last close
$2.92Pivot−0.7%
$2.86Pivot S1−2.7%
$2.8152 week low−4.4%
Indicators
RSI (14)
23.94
Oversold below 30
Oversold
MACD
-2.75
Below its signal line
Bearish
Stochastic
1.3
Near the bottom of its range
Oversold
ADX (14)
21.9
Weak trend
Williams %R
-98.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-145.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−75.2%
Change over 10 sessions
Bearish
ATR (14)
$1.70
Typical daily range, 57.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TNXP
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TNXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in TNXP in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TNXP is in one of them and how their past TNXP trades turned out.
Tonix Pharmaceuticals is a biopharmaceutical company based in Berkeley Heights, New Jersey. It sells TONMYA, a sublingual medicine for fibromyalgia in adults that is designed for bedtime use, along with two prescription sumatriptan products for acute migraine. Its main customers are prescribers in rheumatology, primary care, pain management and neurology practices, reached through national wholesalers and specialty distributors. The company also develops treatments for central nervous system disorders, immunology, infectious diseases and rare diseases.